Breaks Categories: News

ThursdaySep 28, 2023 11:51 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Investigational Drug Focus of Study Published in Peer-Reviewed Journal

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, announced the publication of a scientific paper. The paper, which was published in the “Small” journal, describes the catalytic mechanism of action of CLNN’s investigational drug CNM-Au8(R). “Small” is a leading nanotechnology-focused journal focused on the interface of materials from science, chemistry, physics, engineering, medicine and biology. Titled “A Mechanism Underpinning the Bioenergetic Metabolism-Regulating Function of Gold Nanocatalysts,” the article examines the…

Continue Reading

WednesdaySep 27, 2023 11:54 am

BioMedNewsBreaks – CSurgeries, Sheltowee Network Partner to Relaunch Platform, Revolutionize Surgical Training

CSurgeries, a top-tier online surgical video journal, is collaborating with Sheltowee Network, a leading innovation commercialization company. According to the announcement, the two companies will work together to make high-quality, peer-reviewed surgical content more accessible for medical professionals and students around the world. CSurgeries is redesigning its platform to add new features as well as an invaluable library of surgical videos; the company is also focused on strengthening key industry partnerships. The company will work with Sheltowee Network, which has built a reputation for magnifying business opportunities and catalyzing growth across various sectors through strategic investment of monetary capital and…

Continue Reading

TuesdaySep 26, 2023 12:56 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces Acquisition of World-Class Gene-Editing Platform

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced it has acquired ABBIE, a world-class gene-editing platform that can deliver genetic payloads using non-viral vectors. Through this acquisition, SOHM is well-positioned as a competitive player in the $5.3 billion gene-editing market in 2023, which is expected to grow to $10.8 billion by 2028 at a 15% CAGR. (Source: 2023, Marketsandmarkets.com.) According to the announcement, ABBIE uses targeted integration to insert larger DNA sequences (aka, genetic payload), including full genes, into a desired loci of the target cell’s genome.…

Continue Reading

TuesdaySep 26, 2023 12:48 pm

BioMedNewsBreaks – Safety Shot Holdings Inc. (NASDAQ: SHOT) Announces Board Appointment of the Honorable Jack Brewer, M.Ed.

Safety Shot (NASDAQ: SHOT) today announced that Jack Brewer, M.Ed. has joined the company’s advisory board. Brewer is an ordained minister who possesses a unique combination of expertise in the fields of global economic development, sports and finance through his roles as a successful entrepreneur, executive producer, news contributor and humanitarian. He currently serves as CEO and portfolio manager of The Brewer Group Inc., White House appointee on the U.S. Commission for the Social Status of Black Men & Boys, chair at the America First Policy Institute’s Center for Opportunity Now, as well as well as the founder and executive…

Continue Reading

TuesdaySep 26, 2023 12:39 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Names Experienced Leaders to New Senior Management Positions

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home allowing for the creation of rich data for AI, has appointed two new team leaders. The company announced that Richa Gujarati will serve as senior vice president over product, and Pooja Chatterjee will be vice president over clinical. The two positions are designed to support clinical development and commercialization of HeartBeam’s ambulatory VECG products. With more than 13 years of experience collecting market-level insights and translating those insights into business needs, Gujarati has an impressive…

Continue Reading

FridaySep 22, 2023 1:45 pm

BioMedNewsBreaks – Why PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself. PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions,” a recent article reads. “PaxMedica’s lead programs, PAX-101 and PAX-102, utilize…

Continue Reading

FridaySep 22, 2023 11:45 am

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a company building a portfolio of innovative assets and biotech solutions, was featured in an InvestmentPitch media video that discusses continued development of UNBUZZD(TM), the company’s new rapid detox drink. UNBUZZD(TM) is a proprietary formulation of natural ingredients, vitamins and minerals to help relieve the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle. Kevin Harrington, an original “shark” on the TV hit show Shark Tank and the creator of the infomercial to introduce UNBUZZD(TM), joined the program to discuss his involvement with the product and the impressive team he…

Continue Reading

ThursdaySep 21, 2023 3:16 pm

BioMedNewsBreaks – IBN’s BioMedWire Highlights NanoVibronix Inc.’s (NASDAQ: NAOV) $5M Private Placement

IBN, a multifaceted financial news and publishing company for private and public entities, has announced, through its biotech and biomed brand BioMedWire, the recent private placement offering for NanoVibronix (NASDAQ: NAOV), a medical device company that produces the UroShield(R), PainShield(R) and WoundShield(R) Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices. NanoVibronix in late August entered into definitive agreements for the purchase and sale of an aggregate of 2,906,977 shares of its common stock (or common stock equivalents in lieu thereof), series A-1 warrants to purchase up to 2,906,977 shares of common stock and series A-2 warrants to purchase up to…

Continue Reading

WednesdaySep 20, 2023 10:45 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Closes on $1.33M Registered Direct Offering

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, has closed on a registered direct offering of 1,146,552 of the company’s American Depositary Shares (“ADSs”). According to the announcement, each ADS represented four hundred ordinary shares offered at $1.16 per ADS (or ADS equivalent). The announcement noted that SCNI also issued unregistered warrants in a concurrent private placement comprised of up to 1,146,552 ADSs representing ordinary shares. The warrants have an exercise price of $1.16 per ADS and are immediately exercisable…

Continue Reading

TuesdaySep 19, 2023 12:55 pm

BioMedNewsBreaks – Datasea Inc. (NASDAQ: DTSS) Announces $2.0M Underwritten Public Offering

Datasea (NASDAQ: DTSS), a Nevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology in China, recently announced the pricing of its underwritten public offering of 5,000,000 shares of common stock, each at a public offering price of $0.40, for aggregate gross proceeds of approximately $2.0 million. In addition, the company has granted the underwriters a 45-day option to purchase up to an additional 750,000 shares of common stock at the public offering price per share, less the underwriting discounts, to cover over-allotments, if any. Datasea intends to use the net…

Continue Reading